A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)

drug protocol number

230LE301

drug sponsor

Biogen Idec Research Limited

drug study

BIIB059

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh) , King Khalid University Hospital (Riyadh)

drug status

Ongoing

drug phase